Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-10
2009-10-20
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C536S023100
Reexamination Certificate
active
07605131
ABSTRACT:
The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, and a therapeutic agent for cancer.
REFERENCES:
patent: 2008/0090776 (2008-04-01), Mano et al.
patent: 2004/080980 (2004-09-01), None
patent: 2005/009389 (2005-02-01), None
patent: 2005/016894 (2005-02-01), None
patent: 2005/097765 (2005-10-01), None
patent: 2008/127248 (2008-10-01), None
Willy G. Dirks, et al.; “Expression and Functional Analysis of the Anaplastic Lymphoma Kinase (ALK) Gene in Tumor Cell Lines”; International Journal of Cancer; 2002; pp. 49-56; vol. 100; Wiley-Liss, Inc.
Stephan W. Morris, et al.; “Fusion of a Kinase Gene,ALK, to a Nucleolar Protein Gene,NPM, in Non-Hodgkin's Lymphoma”; Science; Mar. 4, 1994; pp. 1281-1284; vol. 263.
Mami Shiota, et al.; “Anaplastic Large Cell Lymphomas Expressing the Novel Chimeric Protein p80NPM/ALK: A Distinct Clinicopathologic Entity”; Blood; Sep. 1, 1995; pp. 1954-1960; vol. 86, No. 5.
Christian Touriol, et al.; “Further Demonstration of the Diversity of Chromosomal Changes Involving 2p23 in ALK-positive Lymphoma: 2 Cases Expressing ALK Kinase Fused to CLTCL (clathrin chain polypeptide-like)”; Blood; May 15, 2000; pp. 3204-3207; vol. 95, No. 10.
Luis Hernandez, et al.; “TRK-Fused Gene (TFG) is a New Partner ofALKin Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALKTranslocations”; Blood; Nov. 1, 1999; pp. 3265-3268; vol. 94, No. 9.
Larisa V. Debelenko, et al.; “Identification ofCARS-ALKFusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor”; Laboratory Investigation; Sep. 2003; pp. 1255-1265; vol. 83, No. 9.
Ioannis Panagopoulus, et al.; “Fusion of theSEC31L1andALKGenes in an Inflammatory Myofibroblastic Tumor”; International Journal of Cancer; 2006; pp. 1181-1186; vol. 118.
Roberto Piva, et al.; “Ablation of Oncogenic ALK is a Viable Therapeutic Approach for Anaplastic Large-cell Lymphomas”; Blood; Jan. 15, 2006; pp. 689-697; vol. 107, No. 2.
Rongshi Li, et al.; “Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase”; Journal of Medicinal Chemistry; 2006; pp. 1006-1015; vol. 49, No. 3.
Virginie Lacronique, et al.; “A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia”; Science; Nov. 14, 1997; pp. 1309-1312; vol. 278.
Toshinori Iwahara, et al. “Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System”; Oncogene; Jan. 30, 1997; pp. 439-449; vol. 14; Stockton Press.
Luis Hernandez, et al.; “Diversity of Genomic Breakpoints inTFG-ALKTranslocations in Anaplastic Large Cell Lymphomas”; American Journal of Pathology; Apr. 2002; pp. 1487-1494; vol. 160, No. 4.
Brandon Lawrence, et al.; “TPM3-ALKandTPM4-ALKOncogenes in Inflammatory Myofibroblastic Tumors”; American Journal of Pathology; Aug. 2000; pp. 377-384; vol. 157, No. 2.
Martin U. Kuefer, et al.; “Retrovirus-Mediated Gene Transfer ofNPM-ALKCauses Lymphoid Malignancy in Mice”; Blood; Oct. 15, 1997; pp. 2901-2910; vol. 90, No. 8.
Gisele W. B. Colleoni, et al.; “ATIC-ALK: A Novel VariantALKGene Fusion in Anaplastic Large Cell Lymphoma Resulting From the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35)”; American Journal of Pathology; Mar. 2000; pp. 781-789; vol. 156, No. 3.
Tong Zhu, et al.; “Polymer-Supported Synthesis of Pyridone-Focused Libraries as Inhibitors of Anaplastic Lymphoma Kinase”; Journal of Combinatorial Chemistry; 2006; pp. 401-409; vol. 8, No. 3.
Kojo S.J. Elenitoba-Johnson, et al.; “Proteomic Identification of Oncogenic Chromosomal Translocation Partners Encoding Chimeric Anaplastic Lymphoma Kinase Fusion Proteins”; PNAS; May 9, 2006; pp. 7402-7407; vol. 103, No. 19.
Anna V. Galkin, et al.; “Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK”; PNAS; Jan. 2, 2007; Epub2006 Dec, pp. 270-275; vol. 104, No. 1.
Manabu Soda, et al.; “Retroviral Expression Screening of Oncogenes in Primary Non-small-cell Lung Cancer”; O-324; Proceedings of the 65th Annual Meeting of the Japanese Cancer Association; Issued Aug. 28, 2006.
Manabu Soda, et al.; “A Novel Transforming Fusion Kinase Identified in Non-small-cell Lung Cancer”; O-455, Proceedings of the 66th Annual Meeting of the Japanese Cancer Association; Issued Aug. 25, 2007.
Hiroyuki Mano; “A Novel Transforming Fusion Kinase in Lung Cancer”; ML10 Proceedings of the 66th Annual Meeting of the Japanese Cancer Association; Issued Aug. 25, 2007.
K. Pulford, et al.; “The Emerging Normal and Disease-related Roles of Anaplastic Lymphoma Kinase”; Cellular and Molecular Life Sciences; 2004; pp. 2939-2953; vol. 61.
Klarisa Rikova, et al.; “Global Survey of Phosphotyrosine Signaling Indentifies Oncogenic Kinases in Lung Cancer”; Dec. 14, 2007; pp. 1190-1203; vol. 131.
Ultan McDermott, et al.; “Identification of Genotype-correlated Sensitivity to Selective Kinase Inhibitors by Using High-throughput Tumor Cell Line Profiling”; PNAS; Dec. 11, 2007; pp. 19936-19941; vol. 104, No. 50.
Jussi P. Koivunen, et al.; “EML4-ALK Fusion Gene and Sensitivity to an ALK Kinase Inhibitor in Lung Cancer”; Proceedings of the American Association for Cancer Research Annual Meeting; #2373; Apr. 2008; vol. 49.
Kim Sungjoon, et al.; “Therapeutic Application of ALK-Specific Inhibitor Against Epithelial Cancer, Including Lung Cancer”; American Association for Cancer Research Annual Meeting Proceedings Supplement: Late-Breaking Abstracts; Poster Section 18; #LB-41; Apr. 2008.
Daisy Wing-Sze Wong, et al.; “EML4-ALKis a New Oncogene in Non-small Cell Lung Carcinoma Showing Wild-typeEGFRandK-RASFrom Non-smokers”; American Association for Cancer Research Annual Meeting Proceedings Supplement: Late-Breaking Abstracts; Poster Section 19; #LB-62; Apr. 2008.
Sven Perner, et al.; “EML4-ALKFusion Lung Cancer: A Rare Acquired Event”; Neoplasia; Mar. 2008; pp. 298-302; vol. 10, No. 3.
Kazuya Shinmura, et al.; “EML4-ALK Fusion Transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK Fusion Transcripts, in Non-small Cell Lung Carcinomas”; Lung Cancer; 2008; pp. 1-7.
Kentaro Inamura, et al.; “EML4-ALK Fusion is Linked to Histological Characteristics in a Subset of Lung Cancers”; Journal of Thoracic Oncology; Jan. 2008; pp. 13-17; vol. 3, No. 1.
Manabu Soda, et al.; “Identification of the TransformingEML4-ALKFusion Gene in Non-small-cell Lung Cancer”; XP-002464689; Nature; Aug. 2, 2007; pp. 561-567; vol. 448, Nature Publishing Group.
Michal Marzec, et al.; “Inhibition of ALK Enzymatic Activity in T-Cell Lymphoma Cells Induces Apoptosis and Suppresses Proliferation and STAT3 Phosphorylation Independently of Jak3”; XP-002464690; Laboratory Investigation; A Journal of Technical Methods and Pathology; Sep. 19, 2005; pp. 1544-1554; vol. 85, No. 12.
K. Pulford, et al.; “Anaplastic Lymphoma Kinase Proteins in Growth Control and Cancer”; XP-002464691; Journal of Cellular Physiology; Jun. 2004; pp. 330-358; vol. 199; No. 3.
Weihua Wan, et al.; “Anaplastic Lymphoma Kinase Activity is Essential for the Proliferation and Survival of Anaplastic Large-cell Lymphoma Cells”; XP-002464692; Blood; Feb. 15, 2006; pp. 1617-1623; vol. 107; No. 4.
Marc Pollmann, et al.; “Human EML4, a Novel Member of the EMAP Family, is Essential for Microtubule Formation”; XP-002464702; Experimental Cell Research; Jul. 8, 2006; pp. 3241-3251; vol. 312, No. 17.
GenBank accession No. NM—019063; Source: http://www.ncbi.nlm.nih
Furutani Takashi
Kuromitsu Sadao
Mano Hiroyuki
Shindo Nobuaki
Soga Takatoshi
Astellas Pharma Inc.
CureGene K.K.
Fetterolf Brandon J
Sughrue & Mion, PLLC
LandOfFree
EML4-ALK fusion gene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EML4-ALK fusion gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EML4-ALK fusion gene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111682